Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated strong commercial execution, particularly with the recent easing of REMS requirements for its product FILSPARI, which is expected to enhance prescriber adoption rates. The company's pipeline candidate, sparsentan, continues to show accelerating sales and is on a favorable regulatory path in Japan, solidifying its potential as a foundational therapy for IgA nephropathy. Additionally, the cancellation of the AdCom alongside these regulatory advancements has positively influenced market sentiment, reflecting optimism regarding the company's future growth prospects.

Bears say

The negative outlook for Travere Therapeutics's stock is predominantly influenced by uncertainty surrounding the success of its clinical trials, particularly for its late-stage candidate, sparsentan, which focuses on rare kidney disorders. Compounding this risk are concerns regarding the company's ability to secure sufficient funding to advance its drug development, especially in light of recent FDA actions and shifting regulatory practices that have resulted in increased scrutiny and mixed sentiment among investors. Additionally, leadership changes within the company have further exacerbated the volatility and uncertainty in the biopharmaceutical landscape, potentially hindering future growth and investor confidence.

Travere Therapeutics (TVTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 13 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Feb 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.